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Background: The long term use of opioids for the treatment of pain leads to a group of maladaptations which
includes opioid-induced hyperalgesia (OIH). OIH typically resolves within few days after cessation of morphine
treatment in mice but is prolonged for weeks if histone deacetylase (HDAC) activity is inhibited during opioid
treatment. The present work seeks to identify gene targets supporting the epigenetic effects responsible for OIH
prolongation.
Results: Mice were treated with morphine according to an ascending dose protocol. Some mice also received the
selective HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) additionally. Chronic morphine treatment with
simultaneous HDAC inhibition enhanced OIH, and several spinal cord genes were up-regulated. The expression of Bdnf
(Brain-derived neurotrophic factor) and Pdyn (Prodynorphin) were most closely related to the observed behavioral
changes. ChIP (Chromatin immuoprecipation) assays demonstrated that promoter regions of Pdyn and Bdnf were
strongly associated with aceH3K9 (Acetylated histone H3 Lysine9) after morphine and SAHA treatment. Furthermore,
morphine treatment caused an increase in spinal BDNF and dynorphin levels, and these levels were further increased
in SAHA treated mice. The selective TrkB (tropomyosin-receptor-kinase) antagonist ANA-12 reduced OIH when given
one or seven days after cessation of morphine. Treatment with the selective kappa opioid receptor antagonist nor-BNI
also reduced established OIH. The co-administration of either receptor antagonist agent daily with morphine resulted
in attenuation of hyperalgesia present one day after cessation of treatment. Additionally, repeated morphine exposure
induced a rise in BDNF expression that was associated with an increased number of BDNF+ cells in the spinal cord
dorsal horn, showing strong co-localization with aceH3K9 in neuronal cells. Lastly, spinal application of low dose BDNF
or Dynorphin A after resolution of OIH produced mechanical hypersensitivity, with no effect in controls.
Conclusions: The present study identified two genes whose expression is regulated by epigenetic mechanisms during
morphine exposure. Treatments aimed at preventing the acetylation of histones or blocking BDNF and dynorphin
signaling may reduce OIH and improve long-term pain using opioids.
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Opioids have long been accepted as a critical treatment
option for acute forms of pain. As useful as these medica-
tions may be in acute settings, however, a specific group
of maladaptations limits the long term effectiveness of
these drugs including the phenomena of analgesic toler-
ance, physical dependence and opioid-induced hyperalge-
sia (OIH) [1-3]. Moreover, there has been a very sharp rise* Correspondence: psahbaie@stanford.edu
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unless otherwise stated.in the rate of opioid abuse paralleling the rise in their
prescription for the treatment of pain, and opioid abuse
has been recognized by the CDC as a major public health
epidemic in the US [4]. Much recent effort has been
placed on the study of OIH as patients exposed to opioids
through illicit use or for legitimate medical indications for
sustained periods demonstrate heightened pain sensitivity
to experimental pain stimuli, pain during minor proce-
dures and pain after major surgery [5-9]. Many genes
contribute the regulation of opioid adaptations and OIH
[10-12], though mechanisms coordinating the expression
of these genes are very poorly described. It is possible that
by understanding overarching regulatory mechanisms, wetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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or mitigate their impact on our long term pain control
goals.
Epigenetics refers to a collection of processes controlling
how the genome is used without altering DNA sequence
[13-16]. Many of these processes control long term and
sometimes heritable changes in gene expression. Some of
the more commonly studied mechanisms include the con-
trol of covalent histone modifications (acetylation, methy-
lation and etc.), DNA methylation and miRNA synthesis.
One key feature of these epigenetic mechanisms is that
they mediate the responses of specific cell and tissue types
within an organism to changes in environmental factors.
These factors including nutrients, drugs, stress and others
control the expression of groups of genes simultaneously
rather than single genes specifically. Examining the influ-
ence of these environmental factors on concurrent control
over expression of several genes has moved the study of
epigenetics to the forefront of addiction and pain-related
research. For example, the study of cocaine effects on
changes in gene expression in the addiction-related
nucleus accumbens showed that this drug changed the
expression of Fosb, Camk2a, Cdk5, Bdnf and other
addiction-related genes via alterations in histone acetyl-
ation [17]. A recent set of studies from our laboratory
showed that alterations in morphine-induced histone
acetylation in spinal cord tissue helped to regulate mor-
phine tolerance, dependence and OIH [18], though gene
targets for these epigenetic effects were not characterized.
Here, we present studies addressing the hypothesis
that morphine induces OIH via the regulation of histone
acetylation controlling the expression of specific genes
in spinal cord tissue. We selected for these studies a
well-characterized mouse model of tolerance, depend-
ence and OIH used previously to discover genetic and
biochemical factors controlling these maladaptations
[18-22]. We demonstrated in the same mouse model
that OIH largely resolves within 7 days after cessation
of morphine administration, but inhibition of histone
deacetylase (HDAC) activity during morphine treatment
prolonged sensitization for weeks. The present work will
follow up on our previous report to further characterize
the genes responsible for the observed sensitization.
Also, it seems reasonable to focus on the identification
of genes regulated by epigenetic mechanisms during
morphine exposure as an approach to understanding
mechanisms underpinning OIH.
Results
Epigenetic effects of chronic morphine treatment on
spinal cord gene expression
The experimental timeline showing the daily dosing sched-
ule of morphine treatment is represented schematically in
Figure 1A. Here we investigated the effects of morphinetreatment on the expression of a panel of genes implicated
previously in maladaptations to opioids: Fosb, Camk2a,
Cdk5, Bdnf, Pdyn and Grin2a in spinal cord tissue 7 days
after cessation of morphine treatment with and without
co-administration of SAHA [17,18,23]. We found signifi-
cant and sustained up-regulation of several genes. How-
ever, it was only for Bdnf and Pdyn that levels were higher
after simultaneous SAHA and morphine treatment than
morphine or SAHA treatment alone indicating a strong
epigenetic effect (Figure 1B). The Bdnf levels following
SAHA or morphine treatments were not different from
controls (p = 0.36 and p = 0.71 vs. controls respectively, or
each other p = 0.10). Similarly, Pdyn levels following
SAHA or morphine treatments were not different from
controls (p = 0.99 and p = 0.21 vs. controls respectively, or
each other p = 0.21). As SAHA alone treatment failed to
sustain a significant up-regulation of either gene, subse-
quent analyses were conducted comparing morphine and
morphine plus SAHA groups. Moreover, ChIP analysis
demonstrated that the promoter regions of Pdyn and Bdnf
(Exon 4 variant) were more strongly associated with
aceH3K9 (Acetylated histone H3 Lysine9) after morphine
and SAHA treatment than when animals were treated
with morphine alone (Figure 1C). There were no signifi-
cant differences in levels of enrichment for Pdyn (p = 0.11)
or Bdnf Exon 4 (p = 0.13) between vehicle and morphine
treatments. The rodent Bdnf gene contains 9 upstream
exons which can give rise to various splice variants, with
Bdnf mRNA s containing exon 1,2 and 4 being more
transcriptionally important [24,25]. Although the explicit
function of each transcript is unknown, region specific dif-
ferential expression of exons 1 and 4 variants in the ner-
vous system has been observed after cocaine abstinence
[26,27]. The present study implicates exon 4 variant to be
differentially expressed in spinal cord following epigeneti-
cally prolonged OIH.
Effects of HDAC inhibitor treatment on spinal cord BDNF
and dynorphin protein levels after morphine treatment
Next we determined whether the effects of HDAC inhib-
ition during morphine administration on Bdnf and Pdyn
gene expression translated to sustained increases in medi-
ator protein levels in spinal cord tissue. Figure 2A shows
morphine treatment alone caused an increase in the spinal
level of BDNF observable 1 day (Day 5) after the cessation
of morphine treatment, but that the spinal cord BDNF
level was similar to control by 7 days (Day 12). The inclu-
sion of SAHA resulted in significantly increased expres-
sion of BDNF at both time points. The time course of
morphine-enhanced spinal cord dynorphin levels was
similar to that of BDNF, and the inclusion of SAHA with
morphine again prolonged the enhanced dynorphin levels
(Figure 2B). Together with the data in Figure 1, these ob-
servations suggest that the acetylation of H3K9 near the
Figure 1 Epigenetic effects of chronic morphine treatment on spinal cord gene expression. (A) Schematic representation of experimental
timeline showing the daily dosing schedule of morphine treatment. (B-C) Epigenetic effects of escalating dose morphine treatment on spinal
cord gene expression changes after 7 days of washout with/without co-administration of SAHA 50 mg/kg daily. Concomitant HDAC inhibition
leads to significant up-regulation in Bdnf and Pdyn mRNA expression 7 days after cessation of morphine treatment (B). The promoter regions of
Pdyn and Bdnf exon-IV genes were more strongly associated with acetylated histone H3: aceH3K9 (C). Error bars: SEM, n = 6-8/group, *p < 0.05,
**p < 0.01 and ***p < 0.001 for comparison with controls. #p < 0.05, ##p < 0.01 and ###p < 0.001 for comparison with morphine group. Data were
analyzed by two-way ANOVA followed by Bonferroni post-hoc tests.
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Figure 2 HDAC inhibitor treatment increases spinal cord BDNF
and dynorphin protein levels after morphine treatment. SAHA
treatment resulted in significantly increased expression of BDNF after
1 or 7 days since cessation of morphine treatment compared to
vehicle treatment (A). Levels of dynorphin were similarly increased
on day 5 in SAHA and vehicle groups and it was significantly
up-regulated 7 days after morphine and SAHA treatment only (B).
HDAC inhibition was carried out for the duration of escalating dose
morphine administration. Error bars: SEM, n = 5-6/group; *p < 0.05,
**p < 0.01, ***p < 0.001 for comparison with vehicle and ###p < 0.001
for comparison with morphine treatment. Data were analyzed by
two-way analysis of variance (ANOVA) followed by Tukey’s post-hoc
test for multiple comparisons within each timepoint.
Figure 3 Selective acute inhibition of BDNF and prodynorphin
signaling attenuates opioid induced hyperalgesia. Effects of
single dose ANA-12 (TrkB receptor antagonist, 1 mg/kg) or nor-BNI
(KOR antagonist, 1 mg/kg) in the setting of OIH was examined.
Selective antagonism of TrkB (A) receptor and KOR (B) produces a
reversal of mechanical hypersensitivity, whether given once at day 5
(day 1 after completion of morphine protocol) or day 12 (day 7 after
completion of morphine). However, acute ANA-12 but not nor-BNI
administration reversed the sensitization present in the morphine +
SAHA group. Error bars: SEM, n = 6/group, *p < 0.05, **p < 0.01 and
***p < 0.001 for comparison between treatments for each timepoint.
Data for each timepoint were analyzed by one-way ANOVA followed
by Sidak multiple comparisons tests.
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their expression during and after chronic morphine
administration.
Selective inhibition of BDNF and dynorphin signaling
attenuates opioid induced hyperalgesia
In order to test the hypothesized functional links
between BDNF, dynorphin and OIH, we used pharmaco-
logical tools. Specifically, we used selective antagonists
of the TrkB (tropomyosin-receptor-kinase) and κ-opioid
receptor (KOR), ANA-12 and nor-BNI respectively.
Figure 3A-B show that selective antagonism of the TrkBreceptor reduced mechanical sensitization given on day
1 or 7 after cessation of morphine (p < 0.001) or mor-
phine + SAHA (p < 0.001) compared to vehicle treat-
ment. No significant differences were observed for
ANA-12 treatment between morphine or morphine +
SAHA groups (p = 0.54). Treatment with nor-BNI was
not sufficient to reverse hypersensitivity given as a single
dose to mice previously treated with morphine plus
SAHA (p = 0.59), though it could reverse sensitization in
Figure 4 Selective inhibition of BDNF and prodynorphin
signaling during morphine treatment attenuates opioid induced
hyperalgesia. ANA-12 (TrkB receptor antagonist, 0.5 mg/kg) or nor-BNI
(KOR antagonist, 0.5 mg/kg) administration once daily with morphine
during the 4 days of escalating morphine treatment resulted in
attenuation of sensitization on day 5 (A-B). However, only ANA-12 was
associated with less sensitization in the morphine + SAHA group on
day 12 (one week after completion of drug administration). Error bars:
SEM, n = 6/group, ns: p > 0.05, *p < 0.05, **p < 0.01 and ***p < 0.001 for
comparison between treatments for each timepoint. Data for each
timepoint were analyzed by one-way ANOVA followed by Sidak
multiple comparisons tests.
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to vehicle treatment.
The co-administration of either receptor antagonist
agents daily with morphine or morphine plus SAHA for
4 days resulted in attenuation of hyperalgesia on day 5.
Seven days after cessation of drug treatment ANA-12
treated animals that had received morphine (p < 0.001)
or morphine plus SAHA (p < 0.001) continued to have
less mechanical hypersensitivity compared to vehicle
treatment. Though, significant differences were observed
for ANA-12 treatment between morphine and morphine
+ SAHA groups (p < 0.01), the latter group showed sig-
nificant attenuation of hyperalgesia compared to vehicle
treatment (p < 0.01, Figure 4A). However, only nor-BNI
treated animals that received morphine continued to
have less mechanical hypersensitivity (p < 0.05 vs. vehicle
group). The nor-BNI treatment in morphine plus SAHA
treatment group did not produce a lasting effect on
hypersensitivity (p = 0.68, Figure 4A).
Increased spinal cord histone acetylation levels after
morphine treatment promotes BDNF expression
Because our expression data suggested spinal BDNF ex-
pression may be particularly important for OIH after
chronic opioid administration, we determined whether
this mediator is specifically associated with aceH3K9 con-
taining cells in the spinal cord dorsal horn. Figure 5A-C
show an increased number of BDNF+ cells in the dorsal
horn quantified 7 days following completion of morphine
plus SAHA treatment. Additionally, Figure 5D demon-
strates strong co-localization BDNF and aceH3K9 using
double-labeling techniques. To further characterize the
cell types responsible for the increased BDNF production,
double staining techniques using NeuN (neurons) and
GFAP (astrocytes) markers. Figures 6A-D show increased
neuronal production of BDNF after morphine and SAHA
treatment. Additionally, the observed increase was not
strongly associated with spinal astrocytes (Figure 6E). Fur-
ther quantification revealed 82.14 ± 2.05 percent of neur-
onal cells and 6.08 ± 0.44 percent of astrocytes in lamina
I-II to have BDNF positive markers 7 days after comple-
tion of morphine and SAHA treatment. For lamina III-VI,
59.68 ± 3.49 percent of neuronal cells and 5.35 ± 0.61
percent of astrocytes in lamina I-II were BDNF positive
for the same time point.
Intrathecal low dose BDNF and dynorphin A produce
hyperalgesia in resolved OIH
Here we investigated the effects of single intrathecal
dose of BDNF or dynorphin A in mice 7 days after
cessation of morphine treatment. The experiments were
carried out to determine if the increased protein levels
of BNF or dynorphin were directly responsible for
prolonged OIH after morphine and SAHA treatments.Figure 7A shows spinal vehicle treatment to have no
effect on resolved OIH. However application of BDNF
1 ng/5mcl or Dynorphin A 1 nmol (5mcl) in mice 7 days
after cessation of morphine treatment produced robust
mechanical hypersensitivity (Figure 7B-C). The drug
doses selected failed to produce mechanical hypersensi-
tivity in animals previously treated with saline. The
same dose of either agent administered intrathecally has
been shown to produce no significant hyperalgesia in
naïve animals [28,29].
Figure 5 Chronic morphine with SAHA treatment promotes histone acetylation dependent increase in BDNF expression in spinal cord
tissue. (A-B) Micrographs of representative spinal cord dorsal horn sections (Scale bar = 100 micron) showing increased number of BDNF+ cells in
the dorsal horn 7 days after cessation of morphine and SAHA (M + S) treatment. (C) Quantification of BDNF positive cells in 10–15 randomly
(2 slices per mouse) selected high-power fields (HPF, 400X) of spinal cord dorsal horn per animal. (D) BDNF and acetylated H3K9 co-staining in
the M + S treatment group, demonstrating strong association between both. Error bars: SEM, n = 4/treatment group. Data analyzed by unpaired
two tailed student t-tests, **p < 0.01 for differences between treatment conditions.
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Our growing understanding of epigenetic mechanisms has
motivated investigations of the roles of these processes in
many scientific fields relevant to anesthesiology and pain
management including those involving pain mechanisms
and addiction. Our studies were intended to build on
those efforts by refining our understanding of how histone
acetylation, a particularly well established type of epigen-
etic process, might alter opioid-induced hyperalgesia
(OIH), a problematic consequence of chronic opioid
administration [10-12]. We began our studies by selecting
a panel of established genes known to mediate the conse-
quences of chronic opioid administration such as OIH,
tolerance, physical dependence and addiction in CNS
tissues. The selected genes were analyzed further to find
candidates most likely to be under epigenetic control in
spinal cord tissue. The spinal cord is a critical site of
action for opioids with respect to analgesia, and is perhaps
the best studied site of action for mechanisms related to
OIH [10]. Those analyses suggested that both the Bdnf
and Pdyn genes might undergo morphine-induced
changes in expression attributable to histone acetylation.
Further pursuit of these genes revealed that selective
antagonists for BDNF (tropomyosin receptor kinase-B,
TrkB) or dynorphin (κ-opioid receptor, KOR) receptors
could in fact block OIH. Further immunohistochemical
studies localized the spinal expression of BDNF mostly to
neurons within the dorsal horn regions of the spinal cords
of mice. Lastly, spinal application of low dose BDNF ordynorphin produced heperalgesia when OIH was resolved,
while having no effect in opioid naïve groups.
In these studies the TrkB receptor ligand BDNF was
strongly linked to OIH using gene expression, chromatin
immunoprecipitation, immunohistochemical and pharma-
cological data. This neurotrophin has been studied in
association with learning, memory and drug addiction.
Others have suggested that BDNF expressed in various
nervous system tissues exerts actions either facilitating or
countering those of morphine and other opioids. For
example, Meng et al. recently used the conditioned place
preference model of opioid addiction to determine that
BDNF expression in the hippocampus, caudate/putamen
and nucleus accumbens supports drug seeking behavior in
mice [30]. Likewise the administration of low doses of
morphine to neonatal rats caused changes in hippocampal
BDNF expression into adult life suggesting the involve-
ment of long term epigenetic adaptive mechanisms [31].
Consistent with the notion that Bdnf expression might be
controlled by histone acetylation, the regulation of Bdnf
expression through histone acetylation in prefrontal
cortex was observed to mediate the negative affective
component of morphine withdrawal memory in rats [32].
Similarly, cocaine exposure enhanced Bdnf expression in
the nucleus accumbens through enhanced histone acetyl-
ation as well [17]. Our own recent studies and those of
others demonstrated the up-regulation of Bdnf in spinal
cord tissue after several days of morphine exposure in
rats and mice [18,33,34]. The studies of Ferrini et al.
Figure 6 Chronic morphine with SAHA treatment increases the number of BDNF+ expressing spinal cord dorsal horn neurons. (A-C)
Double staining for BDNF and NeuN markers demonstrates strong association with BDNF in neuronal cells (Scale bar = 20 micron). (B-D)
Quantification of double staining for BDNF and NeuN markers reveals increased percentage of neurons expressing BDNF in lumbar spinal cord
dorsal horn tissue (lamina I-II and III-VI) following M + S treatment. (E) Double staining for BDNF and GFAP markers shows less abundant BDNF
expression by astrocytes. Error bars: SEM, n = 4/ treatment group with the numbers of NeuN positive cells (neurons) and BDNF positive neurons
were counted in 10–15 randomly selected (2 slices per mouse) high-power fields (HPF, 400X) of spinal cord dorsal horn per animal. Data analyzed
by unpaired two tailed student t-tests, **p < 0.01 and ***p < 0.001 for differences between treatment conditions.
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studies BDNF released from spinal dorsal horn micro-
glia was shown to down-regulate expression of the
KCC2 K+-Cl− co-transporter in lamina I projection neu-
rons [33]. The immunohistochemical studies done here
showed that the majority of the BDNF in our animals
was neuronal in origin, though we cannot exclude a
functionally relevant amount of BDNF in glia which has
been suggested by others to participate in opioid tolerance
and dependence [33,34]. Although transcription of Bdnf is
controlled by multiple promoters, activity dependent in-
crease in exon 1 and 4 containing transcripts in the braincontributes significantly to neuronal plasticity [35]. Also,
another study has shown BDNF exon 1 containing tran-
scripts to be up-regulated in the ventral tegmental area
following cocaine abstinence [27]. Our study shows the
exon 4 variant to be differentially expressed in spinal cord
following epigenetically prolonged OIH. Furthermore,
while we did not study second messenger system activa-
tion downstream of BDNF production, we did demon-
strate that the TrkB antagonist ANA-12 was very effective
in reversing morphine-related OIH. Similarly, identifica-
tion of spinal second order TrkB expressing projection
neurons mediating such second messenger activation after
Figure 7 Spinal application of low dose BDNF or dynorphin A
produces hyperalgesia in previously morphine treated mice.
Effects of single intrathecal dose of (A) saline (5uL), (B) BDNF 1 ng/5uL
or (C) Dynorphin A 1 nmol (5uL) in mice 7 days after cessation of
morphine/saline treatment OIH were examined. The drug doses
selected fail to produce mechanical hypersensitivity in animals
previously treated with saline. However, in the setting of resolved OIH
both agents produce robust mechanical allodynia. Error bars: SEM,
n = 6/group, **p < 0.01 and ***p < 0.001 for comparison between
treatments for each timepoint. Data for each timepoint were analyzed
by two-way ANOVA followed by Sidak multiple comparisons tests.
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would be of interest [36,37].
The second gene from the spinal multi-gene panel
found to be associated with morphine-induced epigenetic
regulation was Pdyn coding for prodynorphin. The trans-
lation of this gene and subsequent processing ultimately
leads to the production of dynorphin A, dynorphin B and
other peptides. Dynorphin A has a particularly complex
pharmacological profile in that it interacts with both
opioid and non-opioid receptors in spinal pain signaling
pathways [38,39]. Though prodynorphin products can be
released from afferent sensory nerve terminals, the Pdyn
gene is strongly expressed by spinal cord dorsal horn
GABAergic interneurons [40], and these are a possible
source of the Pdyn mRNA measured in our experiments.
Immunohistochemical studies of dynorphin expression in
our animals did not reveal a clear cellular source (data not
shown). Spinal prodynorphin and its component peptides
have been identified as supporting pain in several types of
models including chronic neuropathic [41,42] and inflam-
matory pain [43,44]. It is also the case that epigenetic
regulation of the Pdyn gene has been demonstrated [45].
Most pertinent to present work, spinal Pdyn expression
and dynorphin abundance have been functionally linked
to OIH in rodent studies, though the mechanisms respon-
sible for its up-regulation are not as clearly described
[41,46-48]. We demonstrated that morphine-induced up-
regulation of prodynorphin was epigenetically mediated as
supported by ChIP experiments and results obtained
when using a HDAC inhibitor to pharmacologically in-
crease histone acetylation. The use of the selective KOR
antagonist did reduce OIH when given acutely after cessa-
tion of morphine administration or when given along with
daily doses of morphine. On the other hand, the selective
KOR antagonist was less effective when animals had been
treated with both morphine and the HDAC inhibitor
SAHA. This may be attributable to the possibility that
higher levels of dynorphin peptides present when mor-
phine and SAHA were administered were acting through
other receptors such as the B2 bradykinin receptor to en-
hance nociception [38]. Thus while spinal KOR signaling
may be involved, peptides derived from epigenetically reg-
ulated Pdyn expression may also participate in supporting
OIH via additional non-opioid receptor mechanisms.
The present studies identified Bdnf and Pdyn as genes
epigenetically regulated through the acetylation of histone
proteins consistent with other’s observations. Uchida
et al., for example, reported that histone acetylation
affected Bdnf transcription after peripheral nerve injury
[49]. Both histone proteins H3 and H4 seemed to be
involved in these nerve injury-induced changes whereas
only H3 was observed to undergo morphine-induced
acetylation in our model [18]. Though this regulation was
demonstrated after nerve injury to take place in peripheral
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up-regulation was to enhance BDNF levels in the spinal
cord, and to support nociceptive sensitization. We did not
examine sensory neurons for changes in BDNF expression
after morphine exposure in our experiments. Interestingly,
chronic ethanol exposure leads to the development of
neuroplasticity in the amygdala and the up-regulation of
Pdyn expression possibly by enhanced acetylation of Pdyn
promoter H3 protein at the K9 position similar to what
we observed for the morphine-related effects [45]. Thus
similar epigenetic mechanisms may control Bdnf and
Pdyn expression in different neural tissues to alter noci-
ception, analgesic sensitivity and drug-induced changes in
emotions.Conclusions
The present studies have identified two specific spinal
cord genes whose expression is regulated by epigenetic
mechanisms occurring during morphine exposure.
Though it is unlikely that these are the only genes epige-
netically regulated during chronic morphine treatment,
both Bdnf and Pdyn possibly play a roles in OIH and
other maladaptations to opioids. It may be reasonable,
then, to consider treatments preventing the acetylation
of histones as viable ones in preventing OIH when long
term opioid therapy is required. On the other hand, we
do not at this point know whether agents can be devel-
oped that reduce only epigenetically-regulated opioid
maladaptations and leave intact the many other cellular
processes that might to some degree be epigenetically
regulated as well. More broadly, epigenetic processes
such as histone acetylation may be responsible for inte-
grating the effects of environmental factors like drug ad-
ministration with intrinsic processes like pain signaling
pathways to cause long lasting alterations in neuronal
function. Models similar to those used here could be
used to explore this possibility.Methods
Animal subjects
All animal experiment protocols were approved by the
Veterans Affairs Palo Alto Health Care System Institu-
tional Animal Care and Use Committee (Palo Alto,
California, United States) and complied with the Guide
for the Care and Use of Laboratory Animals available
through the National Academy of Sciences. Male
C57BL/6J mice were obtained from Jackson Laboratory
(JAX, Bar Harbor, ME) at 7–8 weeks of age. Experiments
were done after a 7–10 day acclimation period in our
animal care facility. Mice were housed 4 per cage under
pathogen-free conditions with soft bedding and were
provided food and water ad libitum with a 12:12 light:
dark cycle.Chronic morphine administration
After baseline nociceptive testing, morphine (Sigma Chem-
ical, St. Louis, MO) was subcutaneously administered to
mice on an escalating dose starting from 10 mg/kg up to
40 mg/kg twice per day for 4 days (Figure 1A) in 50–100 μl
volumes of 0.9% NaCl as previously described [18,19,22].
Suberoylanilide hydroxamic acid administration
Suberoylanilide hydroxamic acid (SAHA) was purchased
from Cayman Biochemical (Ann Arbor, Michigan), which
was dissolved in DMSO and diluted with saline (Final
DMSO concentration 70%). Animals received SAHA
50 mg/kg or vehicle, daily via intra-peritoneal (i.p.) injec-
tion (100uL volume) concurrently with/out morning mor-
phine treatment during the chronic dosing paradigm.
ANA-12 and nor-BNI Administration
ANA-12, a BDNF receptor (tropomyosin related kinase
B, TrkB) antagonist and nor-BNI (Norbinaltorphimine),
a selective KOR (κ-opioid receptor) antagonist were pur-
chased from Sigma Chemical (St. Louis, MO). ANA-12
and nor-BNI were dissolved in physiological saline. Ani-
mals received either drug (1 mg/kg for acute on days 5
and 12, or 0.5 mg/kg once daily for concomitant treat-
ment with morphine) or vehicle, daily via i.p. injection
1 hour before testing (100uL volume). The selected drug
doses and timing of administration were in accordance
with prior publications [50-52].
Dynorphin A and BDNF Administration
Intrathecal BDNF 1 ng/5uL, Dynorphin A 1 nmol (5mcl)
or saline (5uL) were carried out in separate groups of mice
7 days after cessation of morphine/saline treatment. BDNF
and Dynorphin A were obtained from Sigma Chemical
(St. Louis, MO) and dissolved in saline. The animals were
gently restrained prior to administration.
Behavioral measurement
Nociceptive testing was done under treatment-blind
conditions. Mechanical allodynia was assessed using nylon
von Frey filaments according to the “up-down” algorithm
described by Chaplan et al. [53] as previously described
[19,22,48]. For these measurements, mice were placed on
mesh platforms within transparent plastic cylinders. After
15 minutes of acclimation, nylon fibers of sequentially
increasing stiffness were applied to the plantar surface of
the hind paw which was left in place 5 sec. Withdrawal of
the hind paw from the fiber was scored as a response. If
no response was observed, the next stiffer fiber was ap-
plied to the same paw; if a response was observed a less
stiff fiber was applied. Testing continued until 4 fibers had
been applied after the first withdrawal response allowing
the estimation of the mechanical withdrawal threshold.
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statistics for analysis [54].
Chromatin Immune Precipitation (ChIP) Assay
Mice were sacrificed using carbon dioxide asphyxiation
and spinal cord lumbar segments (L3-S1) were quickly
dissected in pre-chilled surface. Tissue was flash frozen in
liquid nitrogen and stored at −80°C until use. The assay
was performed following the protocol adopted and refined
previously by our lab [18]. Briefly, small pieces of minced
tissue were cross-linked using 1% formaldehyde and soni-
cated on ice. The sonicated chromatin was clarified by
centrifugation, aliquoted, and snap-frozen in liquid nitro-
gen. To perform ChIP, chromatin (150 μl) was diluted 10-
fold and purified with specific antibody against aceH3K9
(Upstate Biotechnology, Waltham, MA) or IgG as negative
control. Sonicated chromatin 1% was used for input con-
trol. The DNA that was released from the bound chroma-
tin after cross-linking reversal and proteinase K treatment
was precipitated and diluted in low-TE buffer (1 mM Tris,
0.1 mM EDTA). Quantitative PCR of target gene pro-
moter enrichment in ChIP samples was done by ABI
prism 7900HT system using SYBR Green. Five microliters
of input ChIP or IgG sample were used in each reaction in
duplicate for three biological samples in each condition.
Fold enrichment was calculated as a ratio of the ChIP to
mock IgG. An in-plate standard curve determined amplifi-
cation efficiency (AE), and the 100 fold dilution factor for
the input was included. Samples were then normalized to
the saline condition.
Quantification of mRNA
Spinal cord collection method was done as noted above
and qPCR carried out as previously described [18]. Briefly,
total RNA was extracted and RNA concentration was de-
termined spectrophotometric analysis and complementary
DNA was synthesized from total RNA using random hex-
amer priming and a first strand synthesis system (Invitro-
gen, Carlsbad, CA). Expression of genes of interest was
determined by quantitative real-time PCR using ABI
prism 7900HT system (Applied Biosystems). β-actin was
used as an internal control and the expression level of
specific genes was analyzed with ΔΔCt method.
Immunohistochemistry
The technique of immunohistochemical analysis was
described previously [55]. Briefly, the spinal cord was fixed
in 4% paraformaldehyde for 24 h. Blocking of the sections
took place at 4°C for 1 h in phosphate buffered saline con-
taining 10% normal donkey serum, followed by exposure
to the primary polyclonal antibodies against rabbit anti-
BDNF antibody (1:100, Santa Cruz, Dallas, TX ), mouse
anti-acetylated histone H3K9 antibody (1:1000, GeneTex,
Irvine, CA), mouse anti-NeuN (1:500, Millipore) andmouse anti-GFAP (1:500, Millipore) overnight at 4°C.
Sections were then rinsed and incubated with fluorescein-
conjugated secondary antibodies against the primary anti-
bodies (1:500, Jackson ImmunoResearch Laboratories,
West Grove, PA) for 1 h. Double- labeling immunofluores-
cence was performed with donkey anti-mouse IgG conju-
gated with cyanine dye 3, or donkey anti-rabbit IgG
conjugated with fluorescein isothiocyanate secondary anti-
bodies. Confocal laser-scanning microscopy was carried out
using a Zeiss LSM/510 META microscope (Thornwood,
NY). Sections from control and experimental animals were
processed in parallel. Control experiments omitting either
primary or secondary antibody revealed no significant
staining. The numbers of BDNF positive cells, NeuN (neu-
rons) or GFAP (astrocytes) positive cells plus BDNF posi-
tive neurons/astrocytes were counted by a blinded
experimenter in 10–15 randomly (2 slices per mouse) se-
lected high-power fields (HPF, 400X) of spinal cord dorsal
horn per animal.Enzyme immunoassay for BDNF and dynorphin levels
in spinal cord
Mice were first euthanized by carbon dioxide asphyxiation
and spinal cord tissue was harvested by extrusion. Lumbar
spinal cord segments were dissected on a chilled surface.
Dissected tissue was then quick-frozen in liquid nitrogen
and stored at −80°C until required for analysis. Mice lum-
bar spinal cord were homogenized in ice cold 0.9% NaCl
containing a cocktail of protease inhibitors (Roche Ap-
plied Science), centrifuged at 12,000G for 10 min at 4°C
and then supernatant fractions were frozen at −80°C. An
aliquot was subjected to protein assay (Bio-Rad) to
normalize protein levels. BNNF concentrations were mea-
sured in duplicate by using mouse BDNF ELISA kit (Gen-
Way Biotech), and the dynorphin levels were assayed in
duplicate by using Dynorphin EIA kit (Phoenix Pharma-
ceuticals) according to the manufacturer’s instructions.Statistical analysis
All data are expressed as the means ± standard error of
the mean (SEM) unless otherwise noted. The data for
qPCR and ChIP experiments were analyzed by one-way
analysis of variance (ANOVA) followed by Tukey’s post-
hoc test for multiple comparisons. Data from the en-
zyme immunoassay were analyzed by two-way ANOVA
followed by Tukey’s post-hoc test for multiple compari-
sons for each timepoint. The data for mechanical sensi-
tivity were analyzed by one-way ANOVA followed by
Sidak post-hoc test for multiple comparisons for each
timepoint. Comparisons between 2 groups for immune-
staining quantifications involved unpaired t-testing with
two-tail p values. P < 0.05 was considered significant.
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